Patents Assigned to EnLiven Therapeutics, Inc.
  • Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
    Patent number: 11807649
    Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: November 7, 2023
    Assignee: EnLiven Therapeutics, Inc.
    Inventors: Joseph P. Lyssikatos, Samuel Kintz, Li Ren, Qiang Su